- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
UK Biotech Reports Good News
The UK BioIndustry Association’s Q2 Biotech Financing Report finds improved financing, driven primarily by venture capital investment.
The UK BioIndustry Association (BIA) and Clarivate released the Q2 Biotech Financing Report, which found steady growth in financing activity for the UK’s life sciences sector.1
Despite the prevailing global market downturn, UK-headquartered life science and biotech companies secured a total of £382 million ($486.6m) in venture and public financing, up 29% from the previous quarter's £295 million ($375.8m). This growth was largely driven by venture capital investment.
Highlights from the report include:2
- Average size of the 26 venture capital deals between March and the end of May was £13 million ($16.6m)
- Healthy spread of investment between early and late-stage private companies
- IPO activity has remained stagnant across the globe, with no new market launches for UK or European companies
- UK companies raising follow-on financing also faced challenges, securing only £44 million ($50m) this quarter, but showing signs of improvement compared to the previous quarter’s £37 million ($47m)
Steve Bates OBE, CEO of BIA, said in a release, "Our sector is demonstrating resilience and growth amid challenging times. It is fantastic to see venture investors continue to back the UK’s life science companies and even raising new capital themselves, like London-based Medicxi’s $400 million fund, showing that there is more money to deploy in the years to come.
Mike Ward, Global Head of Life Sciences & Healthcare Thought Leadership, Clarivate, said in the same release, “Globally biotech still remains an attractive sector for investment with the sums raised in the second quarter slightly above the first. There was a 26% quarter-on-quarter increase in global VC investments driven mainly by 41% and 42% increases in fundraising among US and European biotechs respectively, although there was a dramatic drop in the amounts put to work by VCs in Asia Pacific biotechs.”
References
- “UK biotech investment increases amidst progress in City of London to unlock new capital.” August 7, 2023. Clarivate.
- “UK biotech financing 2023 March-May 2023” report. BIA. https://biotechfinance.org/q2/
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.
